Sensei Biotherapeutics
SNSE
SNSE
24 hedge funds and large institutions have $2.43M invested in Sensei Biotherapeutics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
24
Holders Change
+1
Holders Change %
+4.35%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
7
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$71K |
| 2 |
CAM
Cresset Asset Management
Chicago,
Illinois
|
+$20.7K |
| 3 |
Morgan Stanley
New York
|
+$12.4K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$189 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$146 |
Top Sellers
| 1 |
NM
Newtyn Management
New York
|
-$674K |
| 2 |
DFO
Duquesne Family Office
New York
|
-$69K |
| 3 |
Millennium Management
New York
|
-$6.01K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.04K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.8K |
